1. Kolomeyer AM, Yu Y, VanderBeek BL. Association of Opioids With Incisional Ocular Surgery. *JAMA Ophthalmol*. 2019 Nov;137(11):1283-1291.
2. Donnenfeld ED, Shojaei RD. Effect of intracameral phenylephrine and ketorolac 1.0%/0.3% on intraoperative pain and opioid use during cataract surgery. *Clin Ophthalmol*. 2019;13:2143–2150.
3. Porela-Tiihonen S, Kaarniranta K, Kokki, H. Postoperative pain after cataract surgery, *J Cataract Refract Surg*. 2013;39(5):789-798.
4. Lesin M, Lozo MD, Duplancic-Sundov Z, et al. Risk factors associated with postoperative pain after ophthalmic surgery - a prospective study. *Ther Clin Risk Manag*. 2016;12:93-102.
5. Apil A, Kartal B, Ekinci M, Cagatay HH, Keles S, Ceylan E, Cakici O. Topical anesthesia for cataract surgery: the patients' perspective. *Pain Res Treat*. 2014;2014:827659. doi: 10.1155/2014/827659.
6. Jiang L, Zhang K, He W, Zhu X, Zhou P, Lu Y. Perceived Pain during Cataract Surgery with Topical Anesthesia: A Comparison between First-Eye and Second-Eye Surgery. *J Ophthalmol*. 2015;2015:383456. doi:10.1155/2015/383456
7. Socea SD, Abualhasan H, Magen O, et al. Preoperative anxiety levels and pain during cataract surgery. *Curr Eye Res*. 2020 Apr;45(4):471-476. doi: 10.1080/02713683.2019.1666996.
8. Porela-Tiihonen S, Kaarniranta K, Kokki, M, Purhonen S, Koki H. A prospective study on postoperative pain after cataract surgery. *Clin Ophthalmol*. 2013;7:1429-1435. doi: 10.2147/OPHTH.S47576.
9. Hah JM, Bateman BT, Ratliff J, Curtin C, Sun E. Chronic opioid use after surgery: Implications for perioperative management in the face of the opioid epidemic. *Anesth Analg*. 2017;125(5): 1733-1740.
10. Brummett CM, Waljee JF, Goesling J, et al. New persistent opioid use after minor and major surgical procedures in US adults. *JAMA Surg*. 2017;152(6) e170504. doi 10.1001/jamasurg.2017.0504
11. Department of Health and Human Services, Centers for Medicare & Medicaid Services. *Medicare Program: Changes to Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs. Evaluation and CY 2020 Proposal for Payment for Non-Opioid Alternatives*. *Fed Regist*. 2019;84(218):61176-61197, 61402. Accessed March 18, 2021. https://www.govinfo.gov/content/pkg/FR-2020-12-29/pdf/2020-26819.pdf
12. Shah A, Hayes CJ, Martin BC. Characteristics of Initial Prescription Episodes and Likelihood of Long-Term Opioid Use — United States, 2006–2015. *MMWR Morb Mortal Wkly Rep*. 2017;66:265–269. doi:[10.15585/mmwr.mm6610a1](http://dx.doi.org/10.15585/mmwr.mm6610a1)
13. Center for Behavioral Health Statistics and Quality. *Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health.* 2015. Accessed December 11, 2020. <http://www.samhsa.gov/data/sites/default/files/NSDUH-FRR1-2014/NSDUH-FRR1-2014.pdf>.
14. Kaye AD, Urman RD, Rappaport Y, Siddaiah H, Cornett EM, Belani K, Salinas OJ, Fox CJ. Multimodal analgesia as an essential part of enhanced recovery protocols in the ambulatory settings. *J Anaesthesiol Clin Pharmacol*. 2019 Apr; 35(Suppl 1): S40–S45. doi:10.4103/joacp.JOACP\_51\_18
15. Jeffries MA, Janecki J, Mayo ML, Wade EC, Castro M, Eisele V. Conscious sedation efficacy of the novel medication, MKO melt (midazolam, ketamine, ondansetron), during cataract surgery. Poster PO001 presented at: The American Academy of Ophthalmology Annual Meeting; October 28, 2018; Chicago IL.
16. Omidria. Prescribing information. Omeros Corporation; December 2017.
17. Hovanesian JA, Sheppard JD, Trattler WB, Gayton JL, Malhotra RP, Schaaf DT, Ng E, Dunn SH. Intracameral phenylephrine and ketorolac during cataract surgery to maintain intraoperative mydriasis and reduce postoperative ocular pain: Integrated results from 2 phase 3 studies. *J Cataract Refract Surg*. 2015;41:2060-2068.
18. Reddy R, Kim SJ. Critical appraisal of ophthalmic ketorolac in treatment of pain and inflammation following cataract surgery. *Clin Ophthalmol*. 2011;5:751-758.
19. Waterbury LD. Alternative drug delivery for patients undergoing cataract surgery as demonstrated in a canine model. *J Ocul Pharmacol Ther*. 2018 Jan/Feb;34(1-2):154-160. doi:10.1089/jop.2017.0048.
20. Katsev DA, Katsev CC, Pinnow J, Lockhart CM. Intracameral ketorolac concentrations at the beginning and end of cataract surgery following preoperative topical ketorolac administration. *Clin Ophthal*. 2017;11:1897-1901.
21. Schoenberger SD, Kim SJ, Sheng J, Calcutt MW. Reduction of vitreous prostaglandin E2 levels after topical administration of ketorolac 0.45%. *JAMA Ophthalmol*. 2014 Feb;132(2):150-4.
22. Wilson, EM, Trivedi RH, Plager, DA. Safety and efficacy data supporting U.S. FDA approval of intracameral phenylephrine and ketorolac 1.0%/0.3% for pediatric cataract surgery: clinical safety and pupil and pain management. *J Cataract Refract Surg*. 2020;46:873-878.
23. Donnenfeld ED. Pain control and reduction of opioid use associated with intracameral phenylephrine/ketorolac 1.0%/0.3% administered during cataract surgery. Submitted for publication, March 2021.
24. Jackson K, Wisely CE, Davis BM, Griffin B, Kim T. Real-world opioid prescribing after cataract surgery among patients who received intracameral phenylephrine and ketorolac 1.0%/0.3%. *Curr Med Res Opin*. 2020. doi:10.1080/03007995.2020.1834373
25. Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, HR6, 115th Congress (2017-2018). Accessed December 12, 2020. https://www.congress.gov/bill/115th-congress/house-bill/6
26. Non-Opioids Prevent Addiction In the Nation (NOPAIN) Act, HR5172, 116th Congress (2019-2020). Accessed January 13, 2021. <https://www.congress.gov/bill/116th-congress/house-bill/5172>
27. Non-Opioids Prevent Addiction In the Nation Act (NOPAIN) Act, S.3067, 116th Congress (2019-2020). Accessed January 13, 2021. <https://www.congress.gov/bill/116th-congress/senate-bill/3067>
28. Jackson KJ, Wisely CE, Kim T. Prevalence of Fentanyl Use in Routine Cataract Surgery. Poster accepted for presentation at: American Society of Cataract and Refractive Surgery Annual Meeting; July 23-27, 2021; Las Vegas, NV.